One of the main things that AstraZeneca's (AZN +0.00%) management highlighted in making the case against Pfizer's proposed acquisition of the British pharma was the large and diverse drug pipeline.
In the video below, health care analysts Michael Douglass and David Williamson discuss a key part of Astra's case -- its respiratory drug portfolio and pipeline.
